Melphalan
- Generic Name
- Melphalan
- Brand Names
- Alkeran, Evomela, Phelinun, Pepaxti
- Drug Type
- Small Molecule
- Chemical Formula
- C13H18Cl2N2O2
- CAS Number
- 148-82-3
- Unique Ingredient Identifier
- Q41OR9510P
- Background
Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is...
- Indication
Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.
...
- Associated Conditions
- Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 216
- Registration Number
- NCT00003789
- Locations
- 🇺🇸
American College of Surgeons Oncology Group, Durham, North Carolina, United States
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Older Patients With Refractory or Relapsed Intermediate-Grade Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00002982
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-06-06
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT00004165
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
Chemotherapy, Holmium Ho 166 DOTMP, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2009-04-03
- Lead Sponsor
- Poniard Pharmaceuticals
- Registration Number
- NCT00045136
- Locations
- 🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States
🇺🇸University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-05-15
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 400
- Registration Number
- NCT00003215
- Locations
- 🇨🇭
Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
🇨🇭Inselspital, Bern, Bern, Switzerland
🇨🇭Ratisches Kantons und Regionalspital, Chur, Switzerland
Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-03-23
- Target Recruit Count
- 67
- Registration Number
- NCT00019786
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver
- Conditions
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Acute Leukemia
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-04
- Lead Sponsor
- Herbert Irving Comprehensive Cancer Center
- Registration Number
- NCT00008190
- Locations
- 🇺🇸
Herbert Irving Comprehensive Cancer Center at Columbia University, New York, New York, United States
Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-04
- Lead Sponsor
- Herbert Irving Comprehensive Cancer Center
- Target Recruit Count
- 75
- Registration Number
- NCT00007995
- Locations
- 🇺🇸
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States
Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT00004250
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.